Parent reported outcomes to measure satisfaction, acceptability, and daily life impact after vaccination with whole-cell and acellular pertussis vaccine in Chile Miguel O’Ryan a,b , Arlene E. Calvo c,⇑ , Mónica Espinoza a , Natalia Vega c , Anne J. Lagomarcino a , Humberto López Castillo d,e , Esteban Puentes f , Denis Macina f a Microbiology and Immunology Program, Institute of Biomedical Sciences, College of Medicine, University of Chile, Santiago, Chile b Millennium Institute of Immunology and Immunotherapy, College of Medicine, University of Chile, Santiago, Chile c University of South Florida, College of Public Health, Panama Program, City of Knowledge, Panama d Department of Health Sciences, College of Health Professions and Sciences, Academic Health Sciences Center, University of Central Florida, Orlando, FL, United States e Department of Population Health Sciences, College of Medicine, Academic Health Sciences Center, University of Central Florida, Orlando, FL, United States f Sanofi Pasteur, Lyon, France article info Article history: Received 27 May 2020 Received in revised form 17 August 2020 Accepted 18 August 2020 Available online 2 September 2020 Keywords: Parent reported outcomes Vaccines DTP Latin America Chile Panama abstract Aim: To compare parental satisfaction and impact on daily life among parents of children receiving whole-cell pentavalent + oral polio vaccine (Arm 1) with an acellular hexavalent vaccine (Hexaxim; Arm 2). Methods: Self-administered electronic questionnaire at vaccination and one week later in six community health clinics of metropolitan Santiago, Chile, exploring parent-reported outcomes on satisfaction, acceptability, and impact on daily life after immunization. Univariate and multivariate analyses were conducted to determine differences in the responses in both groups (a = 0.05). Results: The study enrolled 800 participants and 65% (222 in Arm 1, 296 in Arm 2) were included for according-to-protocol analysis. Demographic characteristics were comparable, except for a higher pro- portion of mothers answering the questionnaire at the 6-month visit. Regardless of the study arm, par- ental knowledge and perception of the immunization practices were good, and there were no differences in vaccination experiences in the prior 5 years. However, satisfaction with vaccination and intention to vaccinate were statistically significantly higher in Arm 2 after the 6-month visit. Also, more parents in Arm 2 reported no disruption in several aspects of the everyday activities of the parent, the child, and other children in the household. Parents in Arm 2 were more likely to be satisfied with the vac- cine received (OR 2.82; 95% CI, 1.22–7.07); return for other vaccine dose (OR 2.62; 95% CI, 1.45–4.84); follow a healthcare professional recommendation (OR 2.24; 95% CI, 1.57–3.21); and, to be confident that the vaccine will not disrupt the family’s daily routine (OR 1.89; 95% CI, 1.32–2.71). Conclusions: Overall, satisfaction, intention for future vaccination, and lower impact on the family daily routine were significantly better in the group receiving the hexavalent vaccine. We also found that health care providers’ recommendations to vaccinate and participants’ access to health services were important factors favoring immunization. Ó 2020 Elsevier Ltd. All rights reserved. 1. Introduction It is estimated that every year, worldwide, Bordetella pertussis causes up to 16 million cases of whooping cough and approxi- mately 195,000 deaths of children [1]. In Chile, infection with B. pertussis is endemic with regular epidemic peaks. In 2011, 2581 cases were reported, 50% occurred in children younger than one year old. Among the 1295 cases reported in children that year, 79% had not completed the primary series of pertussis vaccination [2]. In 2018, the highest incidence occurred among Chilean chil- dren younger than 6 months and the number of cases was much lower after the first year of age [3]. These findings are aligned with recent reports indicating that, during epidemic peaks of pertussis, the highest incidence and severity of disease are observed in https://doi.org/10.1016/j.vaccine.2020.08.046 0264-410X/Ó 2020 Elsevier Ltd. All rights reserved. ⇑ Corresponding author at: USF, COPH, City of Knowledge, #181, Panama City, Panama. E-mail address: calvoae@usf.edu (A.E. Calvo). Vaccine 38 (2020) 6704–6713 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine